Results 241 to 250 of about 898,102 (296)
Some of the next articles are maybe not open access.
European Journal of Medicinal Chemistry, 2022
HDAC inhibitors and NO donors have both demonstrated independently broad therapeutic potential in a variety of diseases. Borretto et al. presented the topic of NO-HDAC dual inhibitors for the first time in 2013 as an attractive new topic. Here we collected the general structure of all synthesized NO-HDAC dual inhibitors, lead compounds, synthesis ...
Razieh Ghodsi, Negar Omidkhah
exaly +3 more sources
HDAC inhibitors and NO donors have both demonstrated independently broad therapeutic potential in a variety of diseases. Borretto et al. presented the topic of NO-HDAC dual inhibitors for the first time in 2013 as an attractive new topic. Here we collected the general structure of all synthesized NO-HDAC dual inhibitors, lead compounds, synthesis ...
Razieh Ghodsi, Negar Omidkhah
exaly +3 more sources
Inside HDAC With HDAC Inhibitors
European Journal of Medicinal Chemistry, 2010Histone deacetylase inhibitors are a large group of diverse molecules intrinsically able to inhibit cell proliferation in various cancer cell lines. Their apoptotic effects have been linked to the modulation in the expression of several regulatory tumor suppressor genes caused by the modified status of histone acetylation, a key event in chromatin ...
Philippe Bertrand
exaly +3 more sources
Immunology & Cell Biology, 2011
Combination antiretroviral therapy (cART) has led to a very substantial reduction in morbidity and mortality in HIV‐infected patients; however, cART alone is unable to cure HIV and therapy is lifelong. Therefore, a new strategy to cure HIV is urgently needed.
Wightman, F +3 more
openaire +3 more sources
Combination antiretroviral therapy (cART) has led to a very substantial reduction in morbidity and mortality in HIV‐infected patients; however, cART alone is unable to cure HIV and therapy is lifelong. Therefore, a new strategy to cure HIV is urgently needed.
Wightman, F +3 more
openaire +3 more sources
2016
Lysine acetylation in proteins is one of the most abundant posttranslational modifications in eukaryotic cells. The dynamic homeostasis of lysine acetylation and deacetylation is dictated by the action of histone acetyltransferases (HAT) and histone deacetylases (HDAC).
Heidi, Olzscha +3 more
openaire +2 more sources
Lysine acetylation in proteins is one of the most abundant posttranslational modifications in eukaryotic cells. The dynamic homeostasis of lysine acetylation and deacetylation is dictated by the action of histone acetyltransferases (HAT) and histone deacetylases (HDAC).
Heidi, Olzscha +3 more
openaire +2 more sources
Inside HDACs with more selective HDAC inhibitors
European Journal of Medicinal Chemistry, 2016Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal mainly against cancers, with four compounds approved by the Food and Drug Administration. During the last five years, several groups have made continuous efforts to improve this class of compounds, designing more selective compounds or compounds with multiple ...
Roche, Joëlle, Bertrand, Philippe
openaire +2 more sources
Teratogenic Activity of HDAC Inhibitors
Current Pharmaceutical Design, 2014Modification of the terminal tails of histones is considered one of the documented mechanisms for epigenetic control of gene expression. Histone deacetylase inhibitors (HDACi) lead to a state of hyperacetylation of histone, a condition that can affect normal gene transcription.
E. Giavini, E. Menegola
openaire +2 more sources
European Journal of Medicinal Chemistry, 2021
'Epigenetic' regulation of genes via post-translational modulation of proteins is the current mainstay approach for the disease therapies, particularly explored in the Histone Deacetylase (HDAC) class of enzymes. Mainly sight saw in cancer chemotherapeutics, HDAC inhibitors have also found a promising role in other diseases (neurodegenerative disorders,
Gargi Nikhil, Vaidya +8 more
openaire +2 more sources
'Epigenetic' regulation of genes via post-translational modulation of proteins is the current mainstay approach for the disease therapies, particularly explored in the Histone Deacetylase (HDAC) class of enzymes. Mainly sight saw in cancer chemotherapeutics, HDAC inhibitors have also found a promising role in other diseases (neurodegenerative disorders,
Gargi Nikhil, Vaidya +8 more
openaire +2 more sources
Histone deacetylase (HDAC) inhibitors are promising new epi-drugs, but the presence of both class I and class II enzymes in HDAC complexes precludes a detailed elucidation of the individual HDAC functions.
Angela Nebbioso +2 more
exaly +2 more sources
Conformal prediction of HDAC inhibitors
SAR and QSAR in Environmental Research, 2019The growing interest in epigenetic probes and drug discovery, as revealed by several epigenetic drugs in clinical use or in the lineup of the drug development pipeline, is boosting the generation of screening data. In order to maximize the use of structure-activity relationships there is a clear need to develop robust and accurate models to understand ...
U. Norinder +4 more
openaire +2 more sources
HDAC inhibitors in parasitic diseases
Immunology & Cell Biology, 2011Parasitic diseases cause significant global morbidity and mortality, particularly in underdeveloped regions of the world. Malaria alone causes ∼800 000 deaths each year, with children and pregnant women being at highest risk. There is no licensed vaccine available for any human parasitic disease and drug resistance is compromising the efficacy of many ...
Andrews, Katherine T. +2 more
openaire +5 more sources

